Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
90% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. ALNY: No Debt )
ALNY' s 10-Year Cash to Debt Range
Min: 6.39   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ALNY's Equity to Asset is ranked higher than
88% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALNY: 0.87 )
ALNY' s 10-Year Equity to Asset Range
Min: -0.76   Max: 0.87
Current: 0.87

-0.76
0.87
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
88% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 39.92
M-Score: 3.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -800.97
ALNY's Operating margin (%) is ranked higher than
57% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. ALNY: -800.97 )
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93   Max: -28.95
Current: -800.97

-14236.93
-28.95
Net-margin (%) -712.79
ALNY's Net-margin (%) is ranked higher than
57% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ALNY: -712.79 )
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3   Max: -27.3
Current: -712.79

-14223.3
-27.3
ROE (%) -44.96
ALNY's ROE (%) is ranked higher than
67% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. ALNY: -44.96 )
ALNY' s 10-Year ROE (%) Range
Min: -336.03   Max: -13.08
Current: -44.96

-336.03
-13.08
ROA (%) -39.18
ALNY's ROA (%) is ranked higher than
65% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. ALNY: -39.18 )
ALNY' s 10-Year ROA (%) Range
Min: -97.61   Max: -5.01
Current: -39.18

-97.61
-5.01
ROC (Joel Greenblatt) (%) -2257.97
ALNY's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. ALNY: -2257.97 )
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2120.98   Max: -168.68
Current: -2257.97

-2120.98
-168.68
Revenue Growth (3Y)(%) -29.60
ALNY's Revenue Growth (3Y)(%) is ranked higher than
62% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ALNY: -29.60 )
ALNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 108
Current: -29.6

0
108
EBITDA Growth (3Y)(%) 65.40
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ALNY: 65.40 )
ALNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.8   Max: 65.4
Current: 65.4

-64.8
65.4
EPS Growth (3Y)(%) 52.80
ALNY's EPS Growth (3Y)(%) is ranked higher than
96% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ALNY: 52.80 )
ALNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7   Max: 52.8
Current: 52.8

-66.7
52.8
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ALNY Guru Trades in Q1 2014

George Soros 3,092 sh (New)
Jim Simons 158,700 sh (New)
Steven Cohen 140,522 sh (+209.28%)
Vanguard Health Care Fund 4,524,800 sh (+10.22%)
Columbia Wanger 902,764 sh (-52.73%)
» More
Q2 2014

ALNY Guru Trades in Q2 2014

Vanguard Health Care Fund 4,973,900 sh (+9.93%)
Jim Simons Sold Out
George Soros Sold Out
Columbia Wanger 784,500 sh (-13.10%)
» More
Q3 2014

ALNY Guru Trades in Q3 2014

Steven Cohen 12,100 sh (New)
Vanguard Health Care Fund 5,277,100 sh (+6.10%)
Pioneer Investments 324,287 sh (unchged)
Columbia Wanger 554,000 sh (-29.38%)
» More
Q4 2014

ALNY Guru Trades in Q4 2014

Bill Frels 2,200 sh (New)
John Griffin 430,000 sh (New)
Paul Tudor Jones 3,540 sh (New)
Pioneer Investments 483,213 sh (+49.01%)
Steven Cohen Sold Out
Vanguard Health Care Fund 5,030,100 sh (-4.68%)
Columbia Wanger 477,700 sh (-13.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: 23.64 )
N/A
P/B 9.90
ALNY's P/B is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. ALNY: 9.90 )
ALNY' s 10-Year P/B Range
Min: 1.58   Max: 21.38
Current: 9.9

1.58
21.38
P/S 174.83
ALNY's P/S is ranked lower than
57% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. ALNY: 174.83 )
ALNY' s 10-Year P/S Range
Min: 3.09   Max: 189.72
Current: 174.83

3.09
189.72
Current Ratio 7.83
ALNY's Current Ratio is ranked higher than
84% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ALNY: 7.83 )
ALNY' s 10-Year Current Ratio Range
Min: 1.88   Max: 9.72
Current: 7.83

1.88
9.72
Quick Ratio 7.83
ALNY's Quick Ratio is ranked higher than
84% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ALNY: 7.83 )
ALNY' s 10-Year Quick Ratio Range
Min: 1.88   Max: 9.72
Current: 7.83

1.88
9.72
Days Sales Outstanding 288.31
ALNY's Days Sales Outstanding is ranked higher than
68% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. ALNY: 288.31 )
ALNY' s 10-Year Days Sales Outstanding Range
Min: 0.57   Max: 288.31
Current: 288.31

0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.60
ALNY's Price/Net Cash is ranked higher than
68% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. ALNY: 16.60 )
ALNY' s 10-Year Price/Net Cash Range
Min: 3.86   Max: 42.87
Current: 16.6

3.86
42.87
Price/Net Current Asset Value 15.70
ALNY's Price/Net Current Asset Value is ranked higher than
67% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. ALNY: 15.70 )
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.75   Max: 39.45
Current: 15.7

3.75
39.45
Price/Tangible Book 9.80
ALNY's Price/Tangible Book is ranked higher than
59% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. ALNY: 9.80 )
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 15.17
Current: 9.8

2.64
15.17
Price/Median PS Value 8.60
ALNY's Price/Median PS Value is ranked higher than
60% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ALNY: 8.60 )
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 7.01
Current: 8.6

0.2
7.01
Earnings Yield (Greenblatt) -4.40
ALNY's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ALNY: -4.40 )
ALNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6   Max: 1781.6
Current: -4.4

-6
1781.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" — the molecules that mediate RNAi — toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
comment on ALNY Mar 09 2013 
comment on ALNY Mar 02 2013 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 06 2009 
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results Feb 17 2009 


More From Other Websites
The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases Apr 23 2015
Biotech Is a Marathon: See Some Biotech People Who Went The Distance In Boston Apr 23 2015
Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog Apr 22 2015
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys -... Apr 22 2015
Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue? - Tale of the Tape Apr 22 2015
Alnylam Says Neurological Drug Passes Midstage Study Apr 21 2015
Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran,... Apr 21 2015
Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran,... Apr 21 2015
Biotech investors brace for updates on key drugs Apr 17 2015
Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog Apr 14 2015
Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an... Apr 13 2015
Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an... Apr 13 2015
Here are 10 local biotechs investing heavily in their future Apr 10 2015
The BBJ’s top real estate stories of the week: April 10, 2015 Apr 10 2015
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick - Tale of the Tape Apr 09 2015
Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference Apr 08 2015
Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference Apr 08 2015
Alnylam to move HQ to former Vertex site in big 2018 biotech shuffle Apr 06 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 06 2015
BioMed Realty Signs Alnylam Pharmaceuticals To 295,000 Square Foot Lease For Class A Laboratory And... Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK